Form 4: Avidity Biosciences Chief Legal Officer Reports Stock and Option Transactions

Avidity Biosciences' Chief Legal Officer, John B. Moriarty, acquired 25,000 restricted stock units and 50,000 stock options on January 6, 2025.

Summary

• John B. Moriarty, Chief Legal Officer of Avidity Biosciences, reported transactions involving the company's stock on January 6, 2025.
• He acquired 25,000 restricted stock units (RSUs), which represent a contingent right to receive one share of common stock each.
• These RSUs will vest in four equal installments on the first four anniversaries of January 6, 2025, contingent on his continued service.
• Moriarty also acquired 50,000 stock options with an exercise price of $31.42.
• These options vest in 48 equal monthly installments from the grant date, fully vesting on January 6, 2029.
• Following these transactions, Moriarty directly owns 50,000 shares of common stock.

Sentiment

Score: 6

Explanation: The document is a routine filing of stock transactions by an executive, which is neither particularly positive nor negative. It is a normal part of corporate governance.

Positives

• The acquisition of stock options and restricted stock units by a key executive could be seen as a positive sign of confidence in the company's future.

Risks

• The vesting of the RSUs and stock options is contingent on the executive's continued employment, which introduces a risk of forfeiture if employment is terminated.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into executive compensation and ownership.

Comparison to Industry Standards

• The vesting schedules for the RSUs and stock options are typical for executive compensation packages in the biotechnology industry.
• Many companies use similar vesting schedules to incentivize long-term performance and retention of key personnel.
• The use of both RSUs and stock options is a common practice to align executive interests with shareholder value.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment as it indicates executive alignment with company performance.

Key Dates

Keywords

Avidity Biosciences, stock options, restricted stock units, insider trading, executive compensation, John B. Moriarty, RNA